Avanir alleged that Par’s and Actavis’ proposed generic products infringe certain patents held by the company.
The law suit was filed based on the response to abbreviated new drug applications (ANDAs) filed by Par and Actavis.
The application was made against Par and Actavis that they tend to market and sell generic versions of the currently approved dose of Nuedexta prior to the expiration of US patents 7,659,282 and RE38,115.
Nuedexta, a combination of two components – dextromethorphan hydrobromide and quinidine sulfate, acts on sigma-1 and NMDA receptors in the brain and treats pseudobulbar affect (PBA).